The transfusion of blood products, especially red cell concentrates, in critically ill patients is controversial and benefits of red cell concentrate transfusion in these patients have not been clearly demonstrated.
The transfusion of blood products, especially red cell concentrates (RCC), in critically ill patients is controversial and has generated much research and debate in the medical literature. The benefits of RCC transfusion in these patients have not been clearly demonstrated, yet up to half of critically ill patients may receive RCC at some time during their intensive care unit (ICU) admission [1] [2] [3] [4] . A number of beneficial effects are postulated to accompany RCC transfu-sion, primarily through increased oxygen carriage to previously hypoxic tissues. RCC transfusion is supported by evidence suggesting that both critically ill and postoperative patients, particularly with concomitant cardiac disease, experience a worse outcome if persistently anaemic 1, 5 . Also, a recent large retrospective study suggested that persistent anaemia in elderly patients admitted with acute myocardial infarction was associated with increased mortality 6 .
However, there are potential disadvantages for critically ill patients receiving blood and blood products, including fluid overload, transfusion reactions, coagulation abnormalities and transmission of infection. More recently, concern has arisen regarding immunomodulation secondary to RCC transfusion, potentially increasing the risk of infection and cancer recurrence 7 . In addition, transfusion of stored "old" RCC may have detrimental effects on microcirculatory flow, increasing tissue ischaemia 8 .
Traditionally, a haemoglobin level (Hb) below 10 g/dl has been used as a simple transfusion trigger in hospitalized patients, although limited clinical data supported this practice. In 1999, Hébert and coworkers published a landmark investigation that demonstrated the benefits of a restrictive blood transfusion practice 9 . A transfusion trigger Hb below 7 g/dl and the maintenance of Hb 7 to 9 g/dl was found to be at least as effective as a more liberal transfusion practice in critically ill patients 9 . Furthermore, patients who received RCC transfusion within the restrictive regimen tended to have a decreased 30day mortality compared with those patients more liberally transfused 9 .
These findings of Hébert and co-workers may have led to a major change in clinical practice within intensive care over the short period of time since publication. In this context, the appropriateness of RCC transfusion in Australian critical care practice was studied recently 4 . As an extension to our involvement in that study, we studied all blood and blood product usage in our intensive care unit over a 28-day period in 2001 (March 14 to April 10 inclusive) to evaluate our single institution transfusion practice compared with current best published evidence and to study the association between transfusion at our ICU and patient outcome.
MATERIALS AND METHODS
The study was conducted in a 24-bed multidisciplinary adult ICU in an Australian universityassociated tertiary referral hospital that is also a state trauma centre. The ICU admits over 2000 patients per annum of whom approximately 40% are cardiac surgical patients. This study was performed as a registered quality assurance activity under the auspices of the hospital quality program and hence the need for individual patient consent was waived.
During March 2001, all patients admitted to the ICU over a consecutive 28-day period were entered into the study. The four-week study period allowed transfusion patterns to reflect the practice of all six consultant intensivists employed in the ICU at that time and minimized bias due to selective physician sampling.
New admissions during the study period were designated as each patient's primary admission and re-admissions during the study period were excluded from analysis. For each patient, data collected included demographic details and the Acute Physiology and Chronic Health Evaluation score (APACHE II) 10 . For the purposes of this study, admissions were classified into three categories (surgical, trauma or medical) and patients in each category were further subdivided according to ICU admission diagnosis.
Patient outcome was recorded as survival status at ICU discharge and at hospital discharge up to 28 days.
The haemoglobin reported by the hospital laboratory for each patient was recorded daily throughout the ICU and subsequent hospital stay. If multiple tests were performed, the first result per day was recorded. A transfusion episode was defined as one or more units of RCC transfused in continuity. When a transfusion episode occurred, the nearest preceding Hb result was designated as the transfusion trigger.
For the purpose of this study, non-RCC blood products included only platelets, fresh frozen plasma (FFP) and cryoprecipitate. When a blood product transfusion occurred, relevant pre-transfusion laboratory values (i.e. platelet count, activated partial thromboplastin time (APTT), International Normalized Ratio (INR) and fibrinogen level) were documented.
Details of RCC transfusion and blood product usage were recorded from 48 hours before ICU admission, during the ICU stay and after discharge to the ward to a maximum of 28 days. All transfusion data were cross-referenced with the hospital haematology department and blood bank service records. Data discrepancies were resolved by reference to the patient medical record.
Statistical Analysis
Continuous data such as age, APACHE II and Hb, were expressed as mean and standard deviation (SD) and compared with t-tests. Categorical variables were compared using Chi-square test or Fisher exact test where appropriate. ICU mortality and hospital mortality censured at 28 days were compared between transfused and non-transfused patient groups using Fisher exact tests, with subsequent adjustments by logistic regression for patient age, ICU admission APACHE II score and the presence or absence of cardiac surgery. The goodness-of-fit of the logistic regression model was assessed by the Hosmer-Lemeshow statistic 11 . Patients lost to follow-up due to hospital discharge were assumed to be alive at 28 days. A P value of less than 0.05 was considered statistically significant for all analyses.
RESULTS
During the 28-day study period, 185 ICU patients were admitted comprising 175 primary and 10 repeat admissions. Of the primary admissions, 72% (126/175) were male, the mean (SD) age was 59.8 (18.4) years and the mean APACHE II score was 12.9 (6.1). The median ICU admission duration was three days (range 1 to 28 days). Forty-one patients (23%) received RCC transfusion during their primary admission. These patients who received RCC transfusion had similar ICU admission diagnoses but a higher mean age and higher mean APACHE II score compared with the non-transfused group. No patient in whom transfusion was clinically indicated had blood products denied or declined during the study period (Table 1) .
A total of 120 RCC units were transfused in ICU, comprising 61 separate transfusion episodes. Fortyone per cent (49/120) of RCC units were given in the first twenty-four hours of admission, and almost three-quarters (87/120, 73%) of all units were transfused by the third ICU day. Transfused patients received an average of 2.9 (median 2, range 1-12) RCC units. Thirty (73%) transfused patients had only one transfusion episode, with another eight (20%) receiving RCC in two separate transfusion episodes. Onethird (20/61) of the transfusion episodes involved a single RCC unit, but only seven patients received a single unit for their entire ICU stay. Thirty patients received RCC in the 48 h prior to ICU admission, including 16 during cardiac surgery.
The mean ICU transfusion trigger Hb was 7.9 (1.2) g/dl ( Figure 1 ). As expected, patients who subsequently received RCC in ICU had lower mean (±SD) admission Hb [9.5 (2.2) g/dl] than patients who were not transfused ( Table 2 ). Importantly, the transfused patients' Hb remained lower than the nontransfused population at ICU discharge.
Forty-four per cent of primary admissions (77/175) followed cardiac surgery. The frequency of RCC transfusion (18/77 versus 23/98: P=1.0) and the distribution of RCC units transfused per person (P=0.73) were similar in cardiac surgery and non-cardiac surgery patients. There was a trend for cardiac surgical patients to receive RCC transfusion at a lower trigger Hb compared to the general ICU population [7.5 (1.0) versus 8.1 (1.2) g/dl: P=0.06].
After discharge from ICU, 13 patients were transfused 26 RCC units, including seven patients who had already received RCC transfusion during their ICU admission, and six who had received RCC in the 48 h prior to their ICU admission. The mean trigger Hb for RCC transfusion following ICU discharge was similar to the ICU Hb trigger [8.3 (0.9) versus 7.9 (1.2) g/dl: P=0.13].
Ten (24%) patients who received RCC also received other blood products during their ICU admission, and three additional patients received only non-RCC blood products ( Overall mortality in ICU was 12% and hospital mortality at 28 days was only slightly greater at 14%. As expected, higher APACHE II scores and greater age were associated with an increased risk of death (Table 4 ). Also as expected, patients admitted following cardiac surgery had much lower ICU mortality (1.3% versus 20.4%) and 28-day hospital mortality (3% versus 22%) than the general ICU population. After adjustment by logistic regression for patient age, APACHE II score and cardiac surgery, RCC transfusion was associated with a reduced mortality both in ICU and in hospital at 28 days ( Figure 2 , Table 4 ).
DISCUSSION
Our study demonstrated that a conservative, restrictive approach to blood product usage is practised in our ICU and that usage of non-RCC blood products within the ICU was minimal during the study period. Only one quarter of patients received blood products during their initial ICU admission. Overall, 23% of ICU patients received RCC transfusion, which is significantly lower than that reported in three recent studies in similar patient groups of intensive care transfusion practice in Europe 3 , the United Kingdom 2 and Canada 1 . However, our relatively low RCC transfusion rate was similar to that reported in the recent Australasian multicentre study to which we contributed 4 .
As early as 1990, Cane stated that in critically ill patients, "routine blood transfusion practices based on arbitrary Hb levels >7 g/dl are no longer consistent with acceptable standards of care" 12 . The publication by Hebert et al in 1999 9 may have accelerated the widespread adoption of a restrictive transfusion practice in critically ill patients. Our study identified a mean trigger Hb prior to RCC transfusion of 7.9 g/dl, with only two transfusion episodes occurring with a trigger Hb >10 g/dl.
Over the last decade, many authorities have published blood transfusion guidelines suggesting that the traditional "10/30" rule described in 1942 13 was outdated [14] [15] [16] [17] [18] . Recently released clinical practice guidelines in Australia recommend that a haemoglobin level of less than 7 g/dl is a reasonable transfusion trigger amongst patients with no known risk factors and that transfusion is unlikely to benefit patients with a haemoglobin level greater than 10 g/dl 19 . Two audits of blood product usage in our hospital published in 1995 and 1999 defined conservative guidelines for local use of blood products and reported inappropriate transfusion rates of 16% 20 and 20% 21 .
Further evidence of the current changes in RCC transfusion practice is the increasing usage of singleunit transfusion. In our study, almost one third of all transfusion episodes were for a single unit only, although only seven patients received only one RCC unit during their ICU stay. In the 1960s, two studies suggested that two-thirds of single unit transfusions were unnecessary 22, 23 , and similarly, our Hospital audit in 1995 identified a high number of single unit transfusions that were classed as inappropriate 20 . As current practice guidelines advise minimizing RCC use for patients requiring transfusion, a single unit may be both adequate and preferable to multiple unit transfusions 16 , suggesting that patients should be reassessed after each RCC unit to determine the need for ongoing transfusion.
Cardiac surgical admissions comprised 40% of ICU patients included in the current study. Unlike the otherwise heterogeneous general ICU population, the majority of cardiac surgical admissions were for planned routine postoperative care and thus were associated with a low mortality rate, consistent with international trends. RCC transfusion management in post-cardiac surgery patients was similar to that of other patients except that the trigger Hb tended to be lower than in general ICU patients. This RCC transfusion rate reflects the consistent implementation of transfusion criteria within our ICU population and it is substantially lower than that reported in an American multicentre study of transfusion practice in coronary artery bypass surgery 24 .
Receipt of RCC transfusion is commonly associated with greater severity of illness and thus higher mortality in published series 2, 3 . Our study also found that transfused patients had a significantly higher APACHE II score and were significantly older than patients who were not transfused. However, after statistical adjustment for these two factors, and also for whether admission followed cardiac surgery, patients in our study who received RCC had a lower ICU and hospital 28-day mortality compared with patients who were not transfused.
Our findings differ from those of the ABC investigators in Europe, who reported a significantly higher ICU and 28-day mortality in patients who received RCC transfusion, after mathematical correction for degree of organ dysfunction, excepting patients with the most severe organ dysfunction 3 . In addition, these authors reported a dose-response relationship between RCC units transfused and mortality, with the highest mortality in those receiving the most RCC units 3 . After attempted statistical correction for patients' admission characteristics, RCC transfusion was associated with an increased the risk of death (OR 1.37; 95% CI 1.02-1.85).
In contrast, improved survival following RCC transfusion was reported in a large retrospective study of 78974 elderly patients who presented with acute myocardial infarction 6 . Those patients with lower haematocrit values on admission had higher 30day mortality rates, and RCC transfusion was associated with a reduced mortality in patients with admission haematocrit values of 33% or less. However, no adjustments for potential confounding factors such as severity of illness or physician decision for active management were made. Both these European and American studies have potential methodological problems 25 , and these apparently conflicting results highlight the lack of randomized clinical data in transfusion medicine.
On the other hand, RCC transfusion may be beneficial in some patient groups, however this benefit may be lost if RCCs are transfused with a more liberal policy. While a multicentre Canadian RCC transfusion audit 1 documented a significantly higher ICU mortality in transfused compared to non-transfused patients, subgroup analysis showed that patients with high APACHE II scores, cardiovascular disease and moderate anaemia actually had a decreased mortality associated with RCC transfusion up to six units 1 . Conversely, patients with low APACHE II scores who received more than six RCC units had a significantly increased mortality 1 . Similarly, in the study by Wu et al, RCC transfusion was associated with increased mortality in patients with admission haematocrit values of 36% or greater 6 .
As with most medical interventions, the risk/benefit ratio associated with RCC transfusion is yet to be clearly defined. At present, the details of best transfusion practice in intensive care patients remain uncertain and further research is required. Whilst liberal and perhaps inappropriate RCC transfusion may be associated with increased mortality, RCC transfusion may reduce mortality in selected critically ill patients.
Our study demonstrates wide acceptance of a restrictive transfusion practice that appears to extend across our ICU population and to the hospital ward after discharge. While our study suggests that RCC transfusion in this context may be associated with improved ICU survival, further prospective studies are needed to support a causal relationship between the receipt of RCC and subsequent changes in ICU and hospital outcome.
